Vision, Integrity, Expertise

Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.

conference call icon 27th Annual ROTH Conference
Soligenix Presentation Webcast

Tuesday, March 10, 2015 at 1:00 PM PDT
Ritz Carlton Laguna Niguel, Dana Point, CA
Non Confidential Introduction
to ThermoVax™

January 2014

View the presentation (pdf)
Corporate Presentation
March 3, 2015

View the presentation (pdf)
Innate Defense Regulators as a Treatment for Melioidosis Presentation
February 2015

View the presentation (pdf)
Thermostable Subunit Vaccine Results in Protective Immunity in Rhesus Macaques in an Inhalational Ricin Model
February 2015

View the presentation (pdf)

Latest News
Tuesday, April 14, 2015
Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric Crohn’s Disease
Tuesday, March 24, 2015
Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results
Wednesday, March 11, 2015
Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine

See more news & events >

Partnering with Us

Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.

Learn More >